London, 22 June 2015 – Technavio, a tech-focused research firm, has published a new report on the global colorectal cancer drugs market, which is expected to grow at a CAGR of nearly 4% from 2015-2019.
The new industry analysis report highlights the growing prevalence of colorectal cancer, which is increasing worldwide. It is ranked as the third most common type of cancer in North America, irrespective of gender.
“According to the Canadian Cancer Society, colorectal cancer affected more than 24,400 people in the country in 2014, and about 9,300 Canadians succumbed to the disease. The number of treatment-seeking patients is expected to increase, which will lead to a rise in the consumption of the drugs through the forecast period,” says Faisal Ghaus, Vice President of Technavio.
The new Technavio report also emphasizes the introduction of biologics that are rapidly becoming the treatment of choice for colorectal cancer. Biologics are targeted therapies, which act only on the malignant cells and do not attack the healthy cells.
“The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab),” says Ghaus.
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
